Technology
Health
Biotechnology

Miragen Therapeutics

$3.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-8.88%) Today
-$0.18 (-5.66%) After Hours

Why Robinhood?

You can buy or sell MGEN and other stocks, options, ETFs, and crypto commission-free!

About

Miragen Therapeutics, Inc. Common Stock, also called Miragen Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Read More Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Employees
80
Headquarters
Boulder, Colorado
Founded
2006
Market Cap
107.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
184.06K
High Today
$3.45
Low Today
$3.00
Open Price
$3.42
Volume
226.28K
52 Week High
$7.94
52 Week Low
$2.20

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical

News

MarketBeatMar 15

Stock Price, News, & Analysis for Miragen Therapeutics

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels i...

1
Guru FocusMar 14

Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

Miragen Therapeutics Inc (NASDAQ:MGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics.

74
Simply Wall StMar 13

What Kind Of Shareholder Owns Most Miragen Therapeutics, Inc. (NASDAQ:MGEN) Stock?

A look at the shareholders of Miragen Therapeutics, Inc. (NASDAQ:MGEN) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership. With a market capitalization of US$79m, Miragen Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of th...

60

Earnings

-$0.33
-$0.28
-$0.23
-$0.18
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.31 per share
Actual
-$0.33 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.